Overview

Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis

Status:
Terminated

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

This is a controlled study to determine the effectiveness and safety of MB12066 in the treatment of adult patients with Nonalcoholic Fatty Liver Disease(NAFLD) except cirrhosis.

Phase:

Phase 2

Details

Lead Sponsor:

KT&G Life Sciences Corp
Yungjin Pharm. Co., Ltd.

Treatments:

Beta-lapachone